EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immune Toxicities in AAV Gene Therapy: Overview for Clinicians

Shestruma Parajuli, Thomas Gallagher iD, Terence R Flotte iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27073196 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Shestruma Parajuli und 2 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Tech Carilion School of Medicine, Roanoke, VA 24016, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Dependovirus, Genetic Vectors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gene therapy using recombinant adeno-associated virus (rAAV) vectors has emerged as a transformative therapeutic modality for genetic disorders, demonstrating high transduction efficiency and a generally favorable safety profile during pre-clinical development. However, serious adverse events, including thrombotic microangiopathy, acute respiratory distress syndrome, hepatotoxicity, myocarditis, cytokine storm, and hemophagocytic lymphohistiocytosis, have been observed across multiple gene therapy clinical trials. Significant efforts have been made to understand the toxicities that cause these adverse events and clinical care for patients receiving gene therapies has evolved to mitigate their effects. These toxicities arise from a complex interplay between the innate and adaptive immune responses directed against the viral capsid and transgene products and are often compounded by pre-existing anti-AAV immunity. Immunomodulatory strategies have been developed to combat these responses to improve the long-term success of gene therapies, and this review provides clinicians managing gene therapy patients with an overview of mechanisms underlying AAV-associated immunotoxicities and a discussion of syndromes and mitigation strategies that have been reported in the clinical care of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyDependovirusGenetic VectorsHumansAnimalsGene Therapy AgentsImmunity, InnateAdaptive Immunity

Stichwörter der Autor:innen

adaptive immunityadeno-associated virus (AAV)gene therapyimmunomodulationimmunotoxicityinnate immunityneutralizing antibody

Autor:innen und Institutionen

  • Virginia Tech Carilion School of Medicine, Roanoke, VA 24016, USA.
  • Department of Genetic and Cellular Medicine, UMass Chan Medical School, Worcester, MA 01655, USA.

ORCID-Profile: Thomas Gallagher, Terence R Flotte

Zitieren

APA

Parajuli, S., Gallagher, T., & Flotte, T. R. (2026). Immune Toxicities in AAV Gene Therapy: Overview for Clinicians. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27073196

Vancouver

Parajuli S, Gallagher T, Flotte TR. Immune Toxicities in AAV Gene Therapy: Overview for Clinicians. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27073196

BibTeX
@article{Parajuli2026,
  author = {Parajuli, Shestruma and Gallagher, Thomas and Flotte, Terence R},
  title = {Immune Toxicities in AAV Gene Therapy: Overview for Clinicians},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27073196}
}
Kostenlos starten →